Tag: telephone

INDIANAPOLIS, June 17, 2025 (GLOBE NEWSWIRE) -- Kite Realty Group Trust (NYSE: KRG) (the “Company”) announced today that, on June 17, 2025, its operating partnership, Kite Realty Group, L.P. (the “Operating Partnership”), priced an offering of $300 million aggregate principal amount of 5.200% Senior Notes due 2032 (the “Notes”) in an underwritten public offering. The Notes will be issued at 99.513% of par value with a yield to maturity of 5.281%. Interest on the Notes is payable semi-annually on February 15 and August 15 of each year, beginning on February 15, 2026. The offering is expected to close on June 27, 2025, subject to the satisfaction of customary closing conditions.

REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof) and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof). In addition, Biomea intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock and pre-funded warrants offered in the public offering. All of the shares, pre-funded warrants and accompanying common stock warrants to be sold in the proposed offering are to be sold by Biomea.

Fiscal 2025 Fourth Quarter Highlights:

FORM 8.3

LOS ANGELES, June 17, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

New Taipei City, Taiwan, June 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (the “Company”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced the pricing of its initial public offering (the “Offering”) of 2,666,667 ordinary shares (the “Ordinary Shares”) at a public offering price of $7.50 per share. The Company expects to receive aggregate gross proceeds of approximately $20 million, before deducting underwriting discounts and other offering expenses. The Ordinary Shares have been approved for listing on the Nasdaq Global Market and are expected to commence trading on June 17, 2025 under the ticker symbol “MENS”. The Offering is expected to close on June 18, 2025, subject to the satisfaction of customary closing conditions. In addition, the Company has granted the underwriters an option (the "Over-Allotment Option"), within 45 days from the date of the final prospectus, to purchase up to an additional 400,000 Ordinary Shares at the public offering price, less underwriting discounts, to cover the Over-Allotment Option, if any.

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Hallador Energy Company (“Hallador” or the “Company”) (NASDAQ:HNRG)on behalf of Hallador stockholders. Our investigation concerns whether Hallador has violated the federal securities laws and/or engaged in other unlawful business practices.

ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against 3D Systems Corporation (“3D Systems” or the “Company”) (NYSE: DDD). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding 3D Systems’ business, operations, and compliance policies, including allegations that: (i) 3D Systems had understated the impact of weakened customer spending on the Company’s business, while overstating its resilience in challenging industry conditions; and (ii) in addition, the updated milestone criteria in the United Partnership would negatively impact the Company’s Regenerative Medicine Program revenue.

MONTREAL, June 16, 2025 (GLOBE NEWSWIRE) -- Boralex inc. (“Boralex” or the “Company”) (TSX: BLX) announces that its 2030 Strategy will be presented at an Investor Day on June 17, 2025, from 10 a.m. to 12:30 p.m., in Toronto.